Chanice Henry | 08/08/2017
Experts have urged that legislation on early access programs needs to be tightened to protect the seriously ill Through expanded early access programs (EAPs), terminally- ill patients that fit certain criteria will be allowed access to unauthorized drugs outside of a clinical trial.These programs aim to give dying patients ethical and controlled strategic access to potentially life- saving medicines before they gain approval. However, the lack of clarity and harmonization of regional regul...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
SmartLab Exchange Europe
22 - 23 February 2027
Leonardo Royal Hotel Amsterdam, Netherlands
Register Now |
View Agenda |
Learn More
Pharma Contract Manufacturing
9 - 11 March 2027
Berlin, Germany
Register Now |
View Agenda |
Learn More